Dotbee.ai

Analysis UroGen Pharma Ltd. (0XOD)

5/30/2024

Analysis UroGen Pharma Ltd. (0XOD)

Analysis of UroGen Pharma Ltd. (0XOD)

UroGen Pharma Ltd. is a pharmaceutical company that focuses on developing novel solutions for urological and oncological conditions. The company's stock symbol is not provided in the data you shared, so I will provide a general analysis based on the information available.

Looking at the historical price data provided, we can see that the stock has been experiencing some fluctuations in price over the past few days. The Relative Strength Index (RSI) values indicate that the stock has been hovering around the mid-range, suggesting a balanced market sentiment.

The Moving Average Convergence Divergence (MACD) indicator shows that the stock has been exhibiting some bearish signals, with the MACD line crossing below the signal line. This could indicate a potential downward trend in the stock price.

Overall, it is important to consider other factors such as market conditions, company news, and industry trends before making any investment decisions regarding UroGen Pharma Ltd.

Earnings

The company's results for the most recent quarter, ending on April 30, 2025, have not been provided at this time. The previous quarter's results, ending on February 27, 2025, were handled by the Transfer Agent. The quarter before that, ending on January 31, 2025, had results released after hours. The results for the quarter ending on October 31, 2024, were not provided at the time. However, for the quarter ending on August 1, 2024, the company had an EPS estimate of 1.32.

Main Statystic 🧠

The data provided includes financials, stock statistics, valuation metrics, stock price summary, and dividends and splits information for a specific company.

In terms of financials, the company has strong operating cash flow and levered free cash flow, with a positive current ratio. The profit margin and operating margin are also healthy, indicating efficient operations. The company's fiscal year ends in September 2023, and it has shown a positive return on assets and return on equity.

Looking at stock statistics, the company has a low short ratio and a significant percentage of shares held by institutions. The stock price has fluctuated between a fifty-two-week low and high, with a positive change over the period.

Valuation metrics show a relatively high PEG ratio and forward PE ratio. The company's market capitalization and enterprise value are substantial, with a high price-to-book ratio and price-to-sales ratio.

The stock price summary includes beta, moving averages, and the range of prices over the past fifty-two weeks.

Lastly, dividends and splits information shows the company's dividend history, payout ratio, and dividend yield metrics. The company has a regular dividend payment schedule and has undergone a stock split in the past.

Income statement 💸

Here are the revenue figures for the company over the past four fiscal years:

- 2020: $274,515,000,000
- 2021: $365,817,000,000
- 2022: $394,328,000,000
- 2023: $383,285,000,000

From these numbers, we can observe that the company experienced a steady increase in revenue from 2020 to 2022, reaching its peak in 2022. However, there was a slight decrease in revenue in 2023 compared to 2022. This trend indicates a period of growth followed by a slight decline in revenue for the company.

Balance Sheet

These are balance sheets. Here are the conclusions based on the provided data:

1. The total assets have been increasing over the years, reaching the highest value in 2023 at $352,583,000,000.
2. Current assets fluctuate slightly each year, with the highest value in 2019 at $162,819,000,000.
3. Non-current assets have been increasing steadily, with the highest value in 2023 at $209,017,000,000.
4. Total liabilities have also been increasing, reaching the highest value in 2023 at $290,437,000,000.
5. Shareholders' equity has been fluctuating, with the highest value in 2020 at $65,339,000,000.
6. The company has been relying more on non-current assets to support its growth, as seen in the increasing trend of non-current assets compared to current assets.
7. The company has been financing its growth through a combination of debt and equity, as indicated by the increase in both liabilities and shareholders' equity over the years.

Cash Flow 💶

This is the cash flow statement. Here are some conclusions we can draw from the data:

1. The company's free cash flow has been fluctuating over the years, with the highest value in 2022 and the lowest in 2020.
2. Operating cash flow has generally been increasing year over year, indicating improved operational efficiency.
3. The company has been consistently paying interest and income taxes, with varying amounts each year.
4. The end cash position has also been fluctuating, reaching its highest value in 2020.
5. Financing activities show a pattern of common stock repurchase, issuance of long-term debt, and payment of dividends.
6. Investing activities include the sale and purchase of investments, as well as capital expenditures.
7. Overall, the company seems to be managing its cash flow effectively, with a focus on operational efficiency and strategic investments.

Earnings estimate

The analysts' estimates for future quarterly and annual earnings per share are as follows:

1. Current Quarter (as of June 30, 2024):
- Average Estimate: $1.33
- Low Estimate: $1.27
- High Estimate: $1.36
- Year Ago EPS: $1.26
- Number of Analysts: 26

2. Next Quarter (as of September 30, 2024):
- Average Estimate: $1.53
- Low Estimate: $1.44
- High Estimate: $1.63
- Year Ago EPS: $1.46
- Number of Analysts: 25

3. Current Year (as of September 30, 2024):
- Average Estimate: $6.59
- Low Estimate: $6.43
- High Estimate: $6.92
- Year Ago EPS: $6.13
- Number of Analysts: 39

4. Next Year (as of September 30, 2025):
- Average Estimate: $7.23
- Low Estimate: $6.40
- High Estimate: $7.90
- Year Ago EPS: $6.59
- Number of Analysts: 39

Based on these estimates, we can see a generally positive trend in the expected earnings per share for both the upcoming quarters and the next two years. The average estimates are showing an increase compared to the year-ago EPS figures, indicating potential growth in earnings for the company.

Revenue estimate

Based on the analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:

1. For the current quarter ending on June 30, 2024, the average sales estimate is $83,776,900,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 24.

2. For the next quarter ending on September 30, 2024, the average sales estimate is $92,375,300,000, with a sales growth of 3% compared to the same quarter last year. The number of analysts providing estimates is 24.

3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $386,681,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates is 37.

4. For the next fiscal year ending on September 30, 2025, the average sales estimate is $411,555,000,000, with a sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates is 37.

These estimates suggest a moderate growth trend in both quarterly and annual sales for the company, with slightly higher growth expected in the next fiscal year compared to the current one.

Growth estimates

Based on the consensus estimates provided, we can draw the following conclusions about the growth rate of the company for different periods:

1. Current Quarter: The estimated growth rate for the current quarter is 5.6%.
2. Next Quarter: The estimated growth rate for the next quarter is 4.8%.
3. Current Year: The estimated growth rate for the current year is 7.5%.
4. Next Year: The estimated growth rate for the next year is 9.7%.
5. Past 5 Years (per annum): The average annual growth rate for the past 5 years is 20.1%.
6. Next 5 Years (per annum): The estimated average annual growth rate for the next 5 years is 11%.

These estimates suggest that the company has experienced significant growth in the past but is expected to see a slightly lower growth rate in the coming years, although still positive. It is important to note that these are analyst estimates and actual performance may vary.

Price target

The analysts' forecast for the future price of the security is as follows:
- Low: $164
- High: $250
- Median: $200
- Average: $202.26
- Current price: $191.57
- Currency: USD

Based on these forecasts, we can see that the analysts have a range of opinions on the future price of the security, with the low end at $164, the high end at $250, and the average at $202.26. The current price is $191.57, which is below the average and median forecasted prices. Investors should consider these forecasts along with other factors when making investment decisions.

MACD of 0XOD

This is not investment advice. Remember to verify the information provided here.

Get access to the full analysis

  • Over 35 000 indexes
  • CFD, Forex, Crypto and Stocks Exchange
  • Over 150 Indicators
  • Pattern and candle analysis
  • Support and resistance levels
  • Fundamental, technical and sentimental analysis
  • Power from AI
Web versionApp StoreGoogle Play

Contacts

Telephone number

+48 32 700 81 66

Email address

[email protected]

Company information

Honey Payment Group S.A. at Al. Aleje Jerozolimskie 65 / 79, 00-697 Warsaw, Poland, Register number KRS 0000335507, NIP 5252859204, REGON 388760204. Honey Payment Group is listed on the Warsaw Stock Exchange (WSE) under the ticker symbol HPG. Link